IFNB1 and in situ carcinoma: Disease-modifying treatments (DMT) including Interferon beta and glatiramer acetate have been shown to delay the development from CIS to CDMS to some extent, and to potentially be able to dampen further tissue damage, including demyelination and axonal loss.